Emerging drugs for the treatment of tobacco dependence: 2014 update

  title={Emerging drugs for the treatment of tobacco dependence: 2014 update},
  author={Muhamad Elrashidi and Jon O. Ebbert},
  journal={Expert Opinion on Emerging Drugs},
  pages={243 - 260}
Introduction: Tobacco dependence remains a global epidemic and the largest preventable cause of morbidity and mortality around the world. Smoking cessation has benefits at all ages but remains challenging for several reasons, among which are the complexities of nicotine addiction and limitations of available pharmacotherapies. Areas covered: This review summarizes current and emerging pharmacotherapies for the treatment of tobacco dependence, including first- and second-line recommended agents… 

The safety of treatments for tobacco use disorder

An overview of current evidence on the safety of first-line pharmacotherapies for the treatment of tobacco use disorder includes nicotine replacement therapy, bupropion sustained-release (SR), and varenicline.

Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking

This article reviewed existing and emerging smoking cessation pharmacotherapies, with a special emphasis on the most promising agents that are currently being investigated, including NRT, bupropion, and varenicline.

Understanding the implications of the biobehavioral basis of nicotine addiction and its impact on the efficacy of treatment

The biobehavioral basis of nicotine addiction, its implications for smoking cessation treatments, the various neurotransmitter systems involved in nicotine addictive effects, and their potential therapeutic value are reviewed.

Pharmacotherapy: Nicotine Replacement Therapy and Other Drugs in Smoking Cessation (Including Vaccination)

There is extensive and solid scientific proof that underlines the efficacy of these three primary drugs in smoking cessation as well as the very high cost-effectiveness of smoking cessation.

Smoking Addiction and Strategies for Cessation

E-cigarettes and vape products are not currently recommended as a smoking cessation aid because of the high number of adverse events, especially among adolescents.

Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers

A comprehensive review of ongoing clinical research into smoking cessation options for heavy-drinking smokers (HDS) through an evaluation of the effect of promising novel pharmacotherapies as well as combination therapies, including varenicline, naltrexone, and the combination of nALTrexone and nicotine replacement therapy (NRT).

Supporting smoking cessation

This review provides an update on evidence based approaches to maximise the effectiveness of the treatment of tobacco dependence and focused on developments since the review by Aveyard and West in 2007.

Randomized Placebo-Controlled Clinical Trials Testing Gemfibrozil for Smoking Cessation and Melatonin for Alcohol-related Sleeping Problems

This thesis focuses on two randomized clinical trials (RCTs) exploring the effect of two therapeutic options one for TUD using lab paradigms for nicotine craving and reinforcement and a brief quit attempt.

Randomized Clinical Trials Investigating Innovative Interventions for Smoking Cessation in the Last Decade.

Clinical trials published within the past 10 years investigating novel smoking cessation pharmacotherapies showed promising results, such as cytisine and endocannabinoid modulators, whereas others failed to produce significant effects.

Pharmacotherapy of Tobacco Use Disorder

First-line pharmacotherapies for tobacco dependence are focused on, with a focus on α4β2 nicotinic acetylcholine receptors, which are thought to play the largest role in nicotine’s reinforcing effects.



Emerging drugs for the treatment of tobacco dependence

Varenicline, an α4β2 nAChR partial agonist, is an emerging drug therapy that modifies tobacco use behavior by acting directly on nicotine receptors in the reward centers of the central nervous system.

Developments in pharmacotherapy for tobacco dependence: past, present and future.

There is a need for studies designed to evaluate the efficacy of pharmacotherapies in populations such as youth, pregnant smokers and smokers with co-occurring mental health problems, and for long-term combination pharmacotherapy combined with improved psychosocial support to enhance medication compliance.

Adverse Effects and Tolerability of Medications for the Treatment of Tobacco Use and Dependence

The benefit: risk ratio is strongly in favour of pharmacotherapy for tobacco dependence treatment in virtually all smokers who are motivated to quit, and the risks of continued tobacco use and the benefits of treatment are strong.

Varenicline and combination nicotine replacement therapy are the most effective pharmacotherapies for treating tobacco use

  • J. Ebbert
  • Medicine, Political Science
    Evidence-Based Medicine
  • 2013
An overview and network meta-analysis of pharmacological interventions for smoking cessation and their comparative efficacies and risks are conducted to help guide treatment, policy and future research.

Pharmacotherapy for Treating Tobacco Dependence

The aim of this review is to present the current evidence supporting the notion that long-term therapy for treating tobacco dependence may be appropriately considered for some tobacco users.

Pharmacological interventions for smoking cessation: an overview and network meta-analysis.

The outcome for benefit is continuous or prolonged abstinence at least six months from the start of treatment, and the outcome for harms is the incidence of serious adverse events associated with each of the treatments.

Clinical Strategies to Enhance the Efficacy of Nicotine Replacement Therapy for Smoking Cessation: A Review of the Literature

A literature review examines emerging clinical strategies to improve NRT efficacy and a brief discussion of emergent NRT products, which may ultimately offer greater efficacy than current formulations.

Neuronal Mechanisms Underlying Development of Nicotine Dependence: Implications for Novel Smoking-Cessation Treatments

The neural substrates, especially nicotinic acetylcholine receptors, that mediate the reinforcing effects of nicotine and the development of nicotine dependence are focused on.

Healthcare financing systems for increasing the use of tobacco dependence treatment.

There is some evidence that healthcare financing systems directed at smokers which offer a full financial benefit can increase the self-reported prolonged abstinence rates at relatively low costs when compared with a partial or no benefit.

Recent advances in the pharmacotherapy of smoking.

It is concluded that pharmacotherapy should be made available to all smokers, because all currently available therapies appear to be equally efficacious, approximately doubling the quit rate compared with placebo.